Cite this article:
Cite this article:
Cite this article:
Cite this article:
Cite this article:
Cite this article:
Cite this article:
The high prevalence of osteoarthritis (OA), as well as the current lack of disease-modifying drugs for OA, has provided a rationale for regenerative medicine as a possible treatment modality for OA treatment. In this editorial, the current status of regenerative medicine in OA including stem cells, exosomes, and genes is summarized along with the author’s perspectives. Despite a tremendous interest, so far there is very little evidence proving the efficacy of this modality for clinical application. As symptomatic relief is not sufficient to justify the high cost associated with regenerative medicine, definitive structural improvement that would last for years or decades and obviate or delay the need for joint arthroplasty is essential for regenerative medicine to retain a place among OA treatment methods. Cite this article:
The Bone &
Joint Journal provides
the latest evidence to guide the clinical practice of orthopaedic
surgeons. The benefits of one intervention compared with another
are presented using outcome measures; some may be specific to a
limb or joint and some are more general health-related quality of
life measures. Readers will be familiar with many of these outcome
measures and will be able to judge the relative benefits of different interventions
when measured using the same outcome tool; for example, different treatments
for
